HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

argatroban (MPQA)

Also Known As:

MPQA; 4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid; Acova; MCI 9038; MCI-9038; MD 805; MD-805; MD805; MMTQAP; Novastan; SmithKline Beecham brand of argatroban; 2-Piperidinecarboxylic acid, 1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-

Networked: 488 relevant articles (66 outcomes, 78 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Piperidines: 12
    - Pipecolic Acids
      - argatroban: 488
- Heterocyclic Acids
  - Pipecolic Acids
    - argatroban: 488

Experts

1.	Hursting, Marcie J: 37 articles (01/2010 - 03/2002)
2.	Jang, Ik-Kyung: 14 articles (10/2010 - 02/2002)
3.	Lewis, Bruce E: 11 articles (09/2008 - 01/2002)
4.	Warkentin, Theodore E: 8 articles (10/2015 - 09/2002)
5.	Greinacher, Andreas: 7 articles (01/2014 - 10/2002)
6.	Walenga, Jeanine M: 7 articles (10/2010 - 01/2002)
7.	Yeh, Robert W: 6 articles (10/2010 - 06/2006)
8.	LaMonte, Marian P: 6 articles (10/2006 - 01/2002)
9.	Koster, Andreas: 5 articles (04/2012 - 09/2006)
10.	Rice, Lawrence: 5 articles (01/2011 - 03/2006)

Related Diseases

1.	Thrombosis (Thrombus) 08/01/2005 - "Successful therapy with argatroban for superior mesenteric vein thrombosis in a patient with congenital antithrombin deficiency." 08/01/2005 - "Argatroban administration would be effective in the treatment of congenital antithrombin deficiency with SMV thrombosis." 01/01/1997 - "Argatroban was demonstrated to be effective in these experimental models of thrombosis. " 01/01/2009 - "Intravenous argatroban improved clinical outcomes and was generally well tolerated in adults with HIT or HIT with thrombosis syndrome (HITTS). " 10/15/2003 - "Compared to historical controls, argatroban demonstrated efficacy in patients with isolated HIT; however, no differences were observed in HIT patients with acute thrombosis. "
2.	Thrombocytopenia (Thrombopenia) 07/01/2004 - "Argatroban treatment improved thrombocytopenia and hypercoagulable state." 08/01/2010 - "After cessation of all heparins and alternative anticoagulation with argatroban, thrombocytopenia was improved and some of occluded grafts were recanalized. " 12/01/2008 - "Even though the cause of this patient's thrombocytopenia was later determined to be idiopathic thrombocytopenic purpura, this is an important case that adds to the literature on use of argatroban during pregnancy." 12/01/2008 - "We describe a 26-year-old pregnant woman with portal vein thrombosis and thrombocytopenia treated with argatroban for possible HIT during her last trimester. " 07/01/2005 - "Thrombocytopenia and hypercoagulability quickly recover to the preheparin level by the appropriate use of argatroban."
3.	Stroke (Strokes) 07/01/2013 - "High-dose argatroban therapy for stroke: novel treatment for delayed treatment and the recanalization mechanism." 05/01/2007 - "Further prospective studies are awaited for evaluating better the efficacy of argatroban on cardioembolic stroke." 01/01/2002 - "A clinical study in Japan found that argatroban administered within 48 h of stroke symptom onset is safe and effective in reducing neurological impairment due to ischemic stroke. " 04/01/2010 - "IV argatroban may be an effective and safe treatment modality for acute ischemic stroke presenting beyond six hours of ischemic symptom onset." 05/01/2007 - "The efficacy of anticoagulant treatment with argatroban on cardioembolic stroke was evaluated retrospectively in this study. "
4.	Hemorrhage 02/01/2013 - "Argatroban did not appear to increase the risk of bleeding in these trials, but evidence provided by historical comparisons is weak. " 05/01/2012 - "The results from this study demonstrate that argatroban should be considered without increased risk for adverse events, including bleeding, in the cardiothoracic intensive care unit after surgery." 01/01/2009 - "Major and minor bleeding rates in argatroban recipients were generally similar to those in historical controls in these studies. " 01/01/2009 - "To study the anticoagulant effect and incidence of bleeding and thrombotic events in patients receiving argatroban, with doses determined using a weight-based nomogram. " 04/01/2006 - "Argatroban was well tolerated in clinical trials of patients with HIT and caused no increase in bleeding risk compared with historical controls. "
5.	Renal Insufficiency (Renal Failure) 01/01/2015 - "Considering its hepatic elimination and its short half-life, argatroban can be considered as a safe therapeutic option in HIT patients at high hemorrhagic risk and with renal failure, particularly in an ICU setting." 12/01/2004 - "Argatroban is eliminated by a hepatic route, making it a practical option for patients with renal insufficiency. " 07/01/2013 - "We now recommend systemic intravenous and local argatroban irrigation to prevent thromboembolic complications in CEA cases with HIT and renal insufficiency. " 10/01/2005 - "We retrospectively reviewed records from 47 patients with HIT and renal failure requiring RRT who underwent 50 treatment courses with argatroban. " 10/01/2005 - "However, few argatroban-treated patients with HIT and renal failure requiring renal replacement therapy (RRT) have been described. "

Related Drugs and Biologics

1.	Heparin (Liquaemin)
2.	Thrombin
3.	Antithrombins
4.	bivalirudin (Angiomax)
5.	phenylmethylpyrazolone
6.	lepirudin (Refludan)
7.	Hirudins
8.	glucuronyl glucosamine glycan sulfate (Vessel)
9.	Factor Xa (Coagulation Factor Xa)
10.	Tissue Plasminogen Activator (Alteplase)

Related Therapies and Procedures

1.	Catheters
2.	Amputation
3.	Renal Replacement Therapy (Therapies, Renal Replacement)
4.	Transplants (Transplant)
5.	Left Heart Bypass